MoonLake Immunotherapeutics
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MLTX in the last 7 days.
No SEC Form 4 filings for $MLTX in the last 30 days.
See all $MLTX insider activity →MoonLake Immunotherapeutics said its Phase III IZAR-1 trial of sonelokimab in biologic-naive adults with active psoriatic arthritis met the primary endpoint at week 16. In the 60 mg arm, 42.1% achieved ACR50. Secondary results included ACR20 66.5%, MDA 41.2%, PASI90 61%. Patients will be followed 52 weeks, with durability data expected in H1 2027. MoonLake is also running IZAR-2 versus AbbVie’s Skyrizi.
MoonLake Immunotherapeutics (MLTX) reported topline Phase 3 IZAR-1 results for Sonelokimab in biologic-naive adults with active psoriatic arthritis. The trial met the Week 16 primary endpoint, with 42.1% on 60 mg achieving ACR50. Secondary results included 66.5% ACR20, 41.2% MDA, and 61% PASI90. Safety showed no new signals. Full readout is expected in H1 2026.
MoonLake Immunotherapeutics (MLTX) shares fell 21.7% pre-open to $14.30 after Phase 3 IZAR-1 topline results for sonelokimab in biologic-naive psoriatic arthritis met the primary endpoint. The company reported 42.1% ACR50 at Week 16, plus 66.5% ACR20 and 61% PASI90. Investors reacted negatively due to a BLA submission for hidradenitis suppurativa and future commercialization, with no current revenue and recent dilutive equity raises.
Recent MLTX coverage spans insider activity, technology and earnings.
Positive Phase III topline increases probability of PsA approval and strengthens the IL-17A/F efficacy narrative, but near-term sentiment may remain cautious given prior selloff.
Positive Phase 3 topline data increases probability of regulatory and commercial success, likely supporting risk-on positioning in MLTX while awaiting durability and safety follow-through.
Clinical success did not translate into near-term valuation support due to a commercialization runway mismatch and ongoing dilution risk.
Positive Phase 3 topline data plus quantified cash runway and near-term regulatory milestone should improve probability-weighted approval and reduce financing risk.
Positive IZAR-1 Week 16 efficacy and no new safety signals increase probability of successful registrational readouts and strengthen valuation support into 2027.
alphai scores every news story that mentions MLTX with an AI model for sentiment and relevance, and aggregates insider trades from MoonLake Immunotherapeutics's SEC EDGAR Form 4 filings. Figures refresh continuously.
MoonLake Immunotherapeutics said its Phase III IZAR-1 trial of sonelokimab in biologic-naive adults with active psoriatic arthritis met the primary endpoint at week 16. In the 60 mg arm, 42.1% achieved ACR50. Secondary results included ACR20 66.5%, MDA 41.2%, PASI90 61%. Patients will be followed 52 weeks, with durability data expected in H1 2027. MoonLake is also running IZAR-2 versus AbbVie’s Skyrizi.
6 min readMoonLake Immunotherapeutics (MLTX) reported topline Phase 3 IZAR-1 results for Sonelokimab in biologic-naive adults with active psoriatic arthritis. The trial met the Week 16 primary endpoint, with 42.1% on 60 mg achieving ACR50. Secondary results included 66.5% ACR20, 41.2% MDA, and 61% PASI90. Safety showed no new signals. Full readout is expected in H1 2026.
3 min readMoonLake Immunotherapeutics (MLTX) shares fell 21.7% pre-open to $14.30 after Phase 3 IZAR-1 topline results for sonelokimab in biologic-naive psoriatic arthritis met the primary endpoint. The company reported 42.1% ACR50 at Week 16, plus 66.5% ACR20 and 61% PASI90. Investors reacted negatively due to a BLA submission for hidradenitis suppurativa and future commercialization, with no current revenue and recent dilutive equity raises.
4 min readMoonLake Immunotherapeutics (MLTX) reported positive topline Week 16 Phase 3 IZAR-1 results for sonelokimab 60 mg in biologic-naive adults with psoriatic arthritis, saying all clinical endpoints were met. It reported 42.1% ACR50 at Week 16 and Q2 2026 net loss of $61.8M, ending with $537.0M cash. R&D was $50.2M. It expects cash runway to mid-2028.
4 min readMoonLake Immunotherapeutics (MLTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results ● Phase 3 IZAR-1 trial in bio-naïve
6 min readReich Kristian (Chief Scientific Officer) sold 52,448 indirectly-held shares of MoonLake Immunotherapeutics (MLTX) at an average of $20.02 ($20.00–$20.02, $1.05M total) across 2 trades over 2026-07-21 to 2026-07-22 under a Rule 10b5-1 trading plan.
3 min readReich Kristian (Chief Scientific Officer) sold 43,700 indirectly-held shares of MoonLake Immunotherapeutics (MLTX) at $20.09 ($0.88M total) on 2026-07-20 under a Rule 10b5-1 trading plan.
2 min readSantos da Silva Jorge (Chief Executive Officer) sold 102,225 shares of MoonLake Immunotherapeutics (MLTX) at an average of $20.02 ($20.01–$20.02, $2.05M total) across 2 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.
2 min readMoonLake Immunotherapeutics says its CFO sold about 39,000 shares under a 10b5-1 plan, with preset timing to avoid trading on material nonpublic information. The article notes the stock fell sharply in late September after disappointing study results and highlights the company has no approved products and no revenue, making shares sensitive to development news.
2 min readSantos da Silva Jorge (Chief Executive Officer) sold 47,775 shares of MoonLake Immunotherapeutics (MLTX) at $20.03 ($0.96M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
1 min read
